1-2.

authors

Philip Smith

references

1. Schulman CC, Robinson M., Denis L., et at (19820: Members of the EORTC. —
2. Kurth K.H., Schroder F.H., Tunn U., et al (1982): Adjuyant chemotherapy for superficial transitional cell bladder carcinoma: preliminary results of an EORTC randomised trail Comparing doxorubiein hydrochloride, ethoglucid and transurethral resection alone. J Urol, 132, pp 258-262. —
3. Green D.F., Robinson M.R.G., Glashan R., et al (1984): Does intravesical chemotherapy prevent invasive bladder cancer? J Urol, 131, pp33-39. —
4. Newling D. (1990): Intravesical therapy in the management of superficial transitional cell carcinoma of the bladder: the experience of the EORTC Cell Group. Brit J Cancer, 61, pp 497-499. —
5. Dalesio O., Schulman C, Syhester R., et al (1983): EORTC GU Group: Prognostic factors in superficial bladder tumours: a study of the EORTC Genito-urinary Tract Cancer Cooperative Group. J Urol, 129, pp 730- 733. —
6. Rubben H., Lutzeyer W., Fischer N., et al (1988): Natural history and treatment of low/high risk superficial bladder tumours. J Urol, 139, pp 283-285. —
7. Tolt P., Pocock R. D.t Ponder B.A.J., O\\\'Sullivan J.P., et al (1982): Prognostic factors in non infiltrating carcinoma of the bladder: a preliminary report. Brit J Urol, 54, p 711. —
8. Tolley D.A., Hargreave T.B., Smith P.H., et al (1988): Effect of intravesical mitomycin C on the recurrence of newly diagnosed superficial bladder cancer; interim report from the Medical Research Council Sub-group on Superficial Bladder Cancer (Urological Cancer Working Party). Brit Med J, 296, p 1759. —
9. Parmar M.K.B., Freedman L.S., Hargreave T.B.,Tolley D.A.. (1989): Prognostic factors of recurrence and follow up policies in the treatment of superficial bladder cancer:report from the British Medical Council Sub-group on Superficial Bladder Cancer (Urological Cancer Working Party). J Urol, 142, pp 284-288. —
10, Someruille J.J.F., Newling D.W.W., Richards B., Robinson M.R.G., Smith P.H. (1985): Mitomycin C in superficial bladder cancer: 24 month follow up. Br J Urol, 57, pp 686-689.